DWYGC was discovered to promote apoptosis in HCC cells by reducing the expression of Wnt-1, Wnt3, β-catenin, FZD2, and GSK3β, leading to a reduction in the expression products of downstream target genes c-myc, cyclin D1, and EpCAM protein (In vivo, Rat, p. o., 360 mg/kg, 22 days, Distilled water (negative control)). The gene discussed is EPCAM; the disease is hepatocellular carcinoma.